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-glucosylceramide has been shown to affect natural
killer T cell function in models of inflammation. We,
therefore , investigated the effects of different -
glycosphingolipids , including -glucosylceramide,
on STAT (signal transducers and activators of
transcription) signaling pathways and determined
whether these effects were mediated by lipid raft
microdomains and/or CD1d molecules. The effects
of - and -structured ligands on the lipid raft pro-
tein flotillin-2 were studied in both natural killer T
hybridoma cells and leptin-deficient mice. To deter-
mine whether CD1d was involved in the effects of
the -glycosphingolipids , an anti-CD1d blocking
antibody was used in a cell proliferation assay sys-
tem. The downstream effects on the protein phos-
phorylation levels of STAT1, STAT3, and STAT6 were
examined in both immune-mediated hepatitis and hep-
atoma models. The effects of -glycosphingolipids on
the STAT signaling pathways were found to be de-
pendent on CD1d. Lipid rafts were affected by both
the dose and ratio of the -glycosphingolipids and
the acyl chain length, and these effects were fol-
lowed by downstream effects on STAT proteins. Our
results show that -glycosphingolipids have bene-
ficial effects in natural killer T cell-dependent im-
mune-mediated metabolic and malignant animal
models in vivo. (Am J Pathol 2009, 174:1390–1399; DOI:
10.2353/ajpath.2009.080841)
Valpha14 invariant natural killer T (iNKT) cells comprise a
unique T cell lineage that shares properties with both
natural killer and memory T cells.1 Lymphocytes in this
subset recognize CD1d-associated glycosphingolipids
via a semi-invariant T cell antigen receptor (TCR), which
is composed of an invariant Valpha14-Jalpha18 chain
paired preferentially with a restricted set of TCR 
chains.2,3 This semi-invariant TCR is specific for glyco-
lipid antigens presented by the major histocompatibil-
ity complex class I-like molecule CD1d.3 CD1 proteins
restrict the antigen-specific responses of NKT cells in
humans and mice. The CD1d-iNKT cell system func-
tions as a sensor for alterations in cellular lipid content,
and CD1d-binding ligands can modulate NKT cell
responses.4,5,6
During NKT cell development, immature, uncommitted
CD4CD8 thymocytes that rearrange the semi-invariant
TCR are directed to the iNKT cell lineage via interac-
tions with endogenous CD1d-associated glycosphin-
golipids.1 The developmental program of iNKT cells is
regulated by a number of signaling cues that have little
or no effect on conventional T cells, including the Fyn/
SAP/SLAM pathway, the nuclear factor-B and T-bet
transcription factors, and interleukin (IL)-15.7–9 The de-
pendency of NKT cell development on Fyn, a Src family
kinase member, distinguishes NKT cells from conventional
T cell populations.10,11 Diverse mutations that interfere with
lysosomal processing and glycolipid degradation also af-
fect NKT cell development. In general, lysosomal storage
diseases can disrupt CD1d antigen presentation, hindering
NKT cell development.4,12,13
The sea sponge-derived agent -galactosylceramide
(GalCer) selectively stimulates NKT cells in vivo.14–16
Administration of GalCer potently activates NKT cells,
induces rapid and robust cytokine production, and acti-
vates a variety of cells of the innate and adaptive immune
systems.17 A truncated GalCer analogue, (2S,3S,4R)-1-
O-(alpha-D-galactopyranosyl)-N-tetracosanoyl-2-amino-
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1,3,4-nonanetriol (OCH), selectively stimulates NKT cells
to produce IL-4 and IL-10. The crystal structure of CD1d
complexed with a short-chain synthetic variant of Gal-
Cer revealed the basis of the high specificity of CD1d for
microbial ligands and demonstrated the restriction of the
-linkage as a unique pathogen-specific pattern-recog-
nition motif. The differential T helper type 1-like and T
helper type 2-like properties of NKT cells arise largely
from differences in ligand binding.18–20 Once loaded
onto the CD1d, the binding of glycosphingolipids by
the Valpha14 Jalpha18 chain of the TCR can be paired
with the binding of an NK1.1 cell-derived Vbeta chain
or any Vbeta8 chain to achieve high-affinity recognition
of the glycolipid. This suggests that the iNKT TCR has
stricter requirements for recognizing GalCer, and it is
assumed that the most rigid part of GalCer, the sugar
moiety, is critical for the interaction.21
-Anomeric D-glycosylceramides are not found in
mammals, and the mechanism of the effect of -struc-
tured ligands is unknown. The results of recent studies
suggest that -structured glycosphingolipids are potent
NKT cell ligands.22 -glucosylceramide (-GC), a natu-
rally occurring glycolipid, is a metabolic intermediate in
the anabolic and catabolic pathways of glycoglycosphin-
golipids.23 Its synthesis from ceramide is catalyzed by
the enzyme glucosylceramide synthase.22 An inherited
deficiency of this lysosomal hydrolase results in high
serum levels of -GC and in Gaucher’s disease. Patients
with Gaucher’s disease have altered humoral and cellular
immune profiles and a distorted NKT lymphocyte number
and function.22 In vitro, CD1d-bound -GC inhibits NKT
cell activation by GalCer.21 -galactosylceramide (-D-
GalCer)-deficient mice exhibit normal NKT cell develop-
ment and function, and cells from these animals can
stimulate NKT hybridomas.24 -D-GalCer (C12) efficiently
reduces the number of detectable NKT cells in vivo with-
out inducing cytokine expression.25
Lipid rafts are highly ordered cholesterol and ganglio-
side-rich platforms abundant in the plasma membrane.
These submicroscopic assemblies facilitate and coordi-
nate close interactions between critical signaling mole-
cules to amplify downstream signaling.26 A number of
proteins involved in signal transduction copurify with lipid
rafts, such as the dually acylated Src-family kinases, LCK
and FYN.27 CD1d is also raft-localized and disruption of
the lipid raft structures blocks efficient signaling of Gal-
Cer through mCD1d, indicating that lipid rafts are re-
quired for efficient signal transduction by CD1d.27,28
The administration of -GC in vivo attenuates NKT
cell-mediated damage in animal models of Con A
hepatitis, immune-mediated colitis, and diabetes.29–31
Preliminary data suggest that -GC has a similar role in
humans.32 The aims of the present study were to in-
vestigate the effects of different -glycosphingolipids
on distinct STAT signaling pathways in vitro and in vivo
in the several models, and to determine whether the
effects are lipid raft microdomain- and CD1d molecule-
dependent in vitro and in some of the tested in vivo
models.
Materials and Methods
Effect of -Structured Ligands on Lipid
Raft-Associated Proteins
Cells
The NKT hybridoma cell line DN32.D3, a thymocyte-
specific clone (kindly provided by Dr. Albert Bendelac,
University of Chicago, Chicago, IL), was used for the
isolation of lipid rafts and for the detection of flotillin-2
within the raft domains. Dually acylated Src-family ki-
nases, LCK and FYN, and STAT 1 and 3 proteins were
tested in this cell line. Cells were stimulated in tissue
culture flasks with 500 ng/ml of -GC, -lactosylceramide
(-LC), a 1:1 combination of -GC and -LC (-IGL), or
PBS. DN32.D3 cells were stimulated by various -glyco-
sphingolipids, and cell proliferation was measured by
3H thymidine incorporation after 72 hours.
Isolation of Lipid Rafts
Flotation studies were performed as described previou-
sly. Aliquots of 3  107 freshly isolated lymphocytes were
washed three times in ice-cold PBS. Cells were lysed in
TNE buffer (150 mmol/L NaCl, 25 mmol/L Tris–HCl, and 5
mmol/L EDTA, pH 7.5) containing 1% Triton X-100 for 30
minutes at 4°C. Supernatants were transferred to TLS-55
(Beckman Instruments, Fullerton, CA) centrifuge tubes
and adjusted to 35% Nycodenz (Sigma-Aldrich, St. Louis,
MO) by adding an equal volume of ice-cold 70% Nyco-
denz dissolved in TNE buffer. TNE buffer with an 8% to
25% Nycodenz linear step gradient was added above the
lysate. Samples were centrifuged at 100,000 g for 4
hours at 4°C. Twelve 180-l fractions were sequentially
collected from the top. The presence of GM1 was deter-
mined by spotting 10 l of each fraction onto a Nytran N
membrane (Schleicher & Schuell, Germany), which was
then blocked with 5% bovine serum albumin in PBS, and
reacted with CTxB- horseradish peroxidase (Sigma, 12.5
ng/ml) for 30 minutes followed by four washes with TBS-T.
Membranes were developed using Western blot-Luminol
Reagent (Santa Cruz Biotechnology, Santa Cruz, CA).
Expression of Raft-Associated Proteins and
Transcription Factors
Equal volumes of each gradient fraction were separated
by SDS-polyacrylamide gel electrophoresis (10% acryl-
amide) and subjected to immunoblot analysis. The follow-
ing antibodies were used: anti-flotillin-2 (1:5000, BD Bio-
sciences, Franklin, NJ), anti-LCK and anti-FYN (1:1000,
NeoMarkers, Stratech, Suffolk, UK), and anti-STAT 1 and 3
(1:1000, Cell Signaling, Danvers, MA). Horseradish peroxi-
dase-coupled antibodies (Jackson Immuno Research, Bar
Harbor, ME) were used as secondary antibodies and de-
tection was performed with Western blot-Luminol Reagent
(Santa Cruz Biotechnology).
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Binding of -Ligands to CD1d Receptors
3H Thymidine Incorporation Assays
Assays were performed using CD1d–NKT restricted hy-
bridomas (DN32.D3) as described previously.33 Anti-CD1d
blocking antibody (5 g/ml; BD Biosciences) was used to
block CD1d receptors.
Animals and Experimental Groups
-GC, -D-GalCer, and -LC were purchased from
Avanti Polar Lipids (Alabaster, AL), dissolved in ethanol,
and emulsified in PBS. Ceramide, iGb3, and GalCer were
purchased from Alexis Biochemicals (San Diego, CA).
Eight-week-old male leptin-deficient ob/ob mice were
purchased from Jackson laboratories. Animals were
housed in the Animal Core of the Hadassah-Hebrew Uni-
versity Medical School. Mice were given standard labo-
ratory chow and water ad libitum and housed under 12-hour
light/dark cycles. Animal experiments were performed ac-
cording to the guidelines of the Hebrew University-Hadas-
sah Institutional Committee for Care and Use of Laboratory
Animals, with the committee’s approval. Leptin-deficient
ob/ob mice (10/group) received daily intraperitoneal injec-
tions of PBS, or 2.5 mg/kg -GC, -LC, or a 1:1 combination
of both (-IGL) for 6 weeks.
Follow-Up Parameters
The expression of hepatic flotillin-2 by mice in both the
soluble and insoluble fractions was determined as de-
scribed above. The effect of alterations in STAT pathways
on metabolic syndrome was determined by glucose tol-
erance tests, determination of serum triglyceride levels,
and assessment of liver weight and histology. Mice un-
derwent a glucose tolerance test on day 60. Glucose was
administered orally (1 g/kg), and serum glucose mea-
surements were performed on tail-vein blood collected
every 15 minutes for 3 hours. Glucose levels were mea-
sured using a standard glucometer. On day 60, serum
triglyceride levels were measured using a spectropho-
tometer (Cobas DP-25P). For histological analysis, a liver
segment from each mouse was fixed in 10% formalde-
hyde and embedded in paraffin. Five sections (5 m)
were stained with H&E and Oil Red-O for quantitative
assessment of hepatic fat and were reviewed by two
pathologists in a blinded manner.34
Downstream Effects of -Ligands on STAT1,
STAT3, and STAT6 Pathways
Animals
Male C57Bl/6 mice (11 to 12 weeks old) were obtained
from Harlan Laboratories (Jerusalem, Israel).
Induction of Hepatitis by Concanavalin A
Concanavalin A (Con A, MP Biomedical, Irvine, CA)
was dissolved in 50 mmol/L Tris (pH 7), 150 mmol/L NaCl,
and 4 mmol/L CaCl2 and injected into the tail vein at a
dose of 500 g/mouse (15 mg/kg). Con A hepatitis was
induced in C57BL/6 mice (10 mice/group) injected 2
hours prior with 0.5 to 75 g/mouse of various -glyco-
sphingolipids, 1 g/mouse of GalCer, a combination of
both, or 100 l PBS. Animals were sacrificed 10 hours
after the -glycolipid injections, 8 hours after injection of
ConA.
Expression of STAT Proteins
The levels of STAT1, phosphorylated STAT1, and
STAT6 were determined by Western blot analysis of
splenocytes harvested from mice in all groups. Spleno-
cytes were lysed in 200 l ice-cold RIPA buffer contain-
ing protease inhibitor cocktail (Sigma). Lysates were left
on ice for 30 minutes, then centrifuged twice for 10 min-
utes in 4°C. Supernatants were taken and protein con-
centrations were determined by Bradford assay (Bio-
Rad, Hercules, CA). - Actin (Abcam, UK) was used as a
loading control. Proteins were resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. Proteins were
transferred to nitrocellulose membranes and blocked with
5% nonfat dry milk. The following antibodies were used:
STAT1, STAT6, and phospho-specific STAT1-Tyr701 (Cell
Signaling35). Horseradish peroxidase-coupled antibodies
(Jackson Immuno Research) were used as secondary an-
tibodies, and detection was performed using Western blot-
Luminol Reagent (Santa Cruz Biotechnology).
Isolation of Splenocytes and Intrahepatic Lymphocytes
Splenocytes and intrahepatic lymphocytes were isolated
as follows: livers and spleens were placed in RPMI-1640 
fetal bovine serum and spleens were filtered through a
70-m nylon cell strainer36 and centrifuged (1250 rpm for
7 minutes) to remove the debris. Red blood cells were
lysed with 1 ml of cold 155 mmol/L ammonium chloride
lysis buffer and immediately centrifuged (1250 rpm for 3
minutes). Splenocytes were then washed and resus-
pended with 1 ml RPMI  fetal bovine serum (5%). The
remaining connective tissue was removed. Cell viability,
as assessed by trypan blue staining, was above 90%. For
intrahepatic lymphocytes, livers were first filtered through
a stainless steel mesh (size 60, Sigma) and the cell
suspension was placed in a 50-ml tube for 5 minutes to
allow cell debris to settle to the bottom. Lymphoprep (10
ml; Ficoll, Axis-Shield PoC AS, Oslo, Norway) was slowly
placed under the same volume of cell suspension in
50-ml tubes. The tubes were then centrifuged at 1800
rpm for 18 minutes. Cells in the interface were collected
and moved to new tubes, which were centrifuged again
at 1800 rpm for 10 minutes, to obtain a pellet of cells
depleted of hepatocytes in a final volume of 250 l.
Approximately 1  106 cells/mouse liver were recovered.
Following lymphocyte isolation, flow cytometry was per-
formed using 1  106 lymphocytes in 100 l PBS. To
determine the percentage of NKT lymphocytes, we used
phycoerythrin-conjugated Cy5 anti-mouse CD3 and anti-
mouse NK1.1 antibodies (eBioscience, San Diego, CA).
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Assessment of the Effect of -Glycosphingolipids
on Liver Damage
Liver Enzymes
Animals were sacrificed 10 hours after the glycolipid
injections and 8 hours after the injection of Con A. Sera from
individual mice were obtained. Serum aspartate amino-
transferase (AST) and alanine aminotransferase (ALT) ac-
tivities were determined using a Kodak automatic analyzer.
Terminal Deoxynucleotidyl Transferase-Mediated dUTP
Nick-End Labeling Staining
The terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL) assay was performed on
paraffin-embedded liver sections using a commercially
available kit, according to the manufacturer’s instructions
(In Situ Cell Death Detection kit, Fluorescein, Roche Diag-
nostics, Germany). TUNEL-positive cells were character-
ized morphologically by staining with 4,6-diamidino-2-phe-
nylindole. Slides were visualized using a Zeiss Axioplan
fluorescence microscope (Oberkochen, Germany). Images
were collected with a cooled charge-coupled device cam-
era (Quantix Corp., Cambridge, MA) using Image Pro soft-
ware. For cell counting in tissues processed for TUNEL
staining, five standardized microscopic fields (20 objective)
per slide (per animal) were digitally photographed under the
fluorescence microscope and then quantified using Total Lab
software (Phoretix, Durham, NC).
Alterations of STAT1, STAT4, and STAT6
Phosphorylation Levels Induced by Different
Ratios and Doses of -Glycosphingolipids
Different ratios and doses of -ligands were investigated
in the Con A hepatitis model. Thirteen groups of mice
(Table 1), 10 mice per group, were treated with Con A
and different ratios and doses of -glycosphingolipids as
described above. STAT1, STAT4, and STAT6 phosphor-
ylation levels were examined. The effects of signaling
pathway alterations on NKT lymphocyte distribution were
determined by fluorescent-activated cell sorting analysis of
intrahepatic and intrasplenic NKT lymphocytes. The effects
on immune-mediated hepatitis were evaluated by TUNEL
assay, serum interferon- levels, and enzyme levels.
Influence of Acyl Chain Length on the
Immunomodulatory Effects of -Structured
Ligands
Athymic BALB/c mice (8 mice/group) were sublethally
irradiated and transplanted with Hep3B hepatocellular
carcinoma, followed by daily intraperitoneal injections of
-GC or -LC with 8 or 12 carbons in the acyl chain
(-GC8, -GC12, -LC8, or -LC12, respectively) or PBS
for 42 days. The tumor volume in each animal was as-
sessed. To determine the effect of acyl chain length on NKT
distribution and intrahepatic CD8 lymphocyte trapping, flu-
orescent-activated cell sorting analysis was performed on
lymphocytes isolated from the spleen and liver.
Statistical Analysis
Comparisons of two independent groups were performed
using the Student’s t-test. Multiple comparisons were
assessed by the analysis of variance test. All tests ap-
plied were two-tailed, and a P value of 0.05 or less was
considered to be statistically significant.
Results
-Glycosphingolipids Affect Lipid Raft-Associated
Markers
Administration of -structured glycosphingolipids to NKT
hybridoma cells (DN32.D3) in vitro in the presence of
antigen presenting cells led to flotillin-2 recruitment to
lipid raft fractions (Figure 1A, upper panel). Recruitment
of the Src-family kinase LCK was not affected (data not
shown). GM1, a lipid raft marker, was detected in cell
membrane fractions 1–6, but no significant effects of
-glycosphingolipids on its content were noted (Figure
1A, lower panel).
In vivo administration of -glycosphingolipids to leptin-
deficient ob/ob mice increased the expression of hepatic
flotillin-2 in both the soluble and insoluble fractions. These
alterations in signaling pathways were associated with the
alleviation of NKT cell-dependent metabolic derangements
in ob/ob mice. -glycosphingolipids administration amelio-
rated glucose intolerance (-GC and -IGL, Figure 1B),
decreased serum triglyceride levels (-IGL), reduced intra-
hepatic fat accumulation (-GC, -LC, and -IGL), and
decreased liver weight (-GC, -LC, and -IGL).
Table 1. Effects of Different Ratios and Doses of
-Glycosphingolipids on Liver Enzyme Activity in
the Con A Hepatitis Model (Percentage of
Control)
Group Treatment ALT (%) AST (%)
A PBS 100 100
B GC 0.5 mg/mouse 81.63 80.46
C LC 0.5 mg/mouse 77.54 78.06
D IGL (0.25  0.25)
mg/mouse
63.32 81.23
E GC 1.5 mg/mouse 58.40 61.00
F LC 1.5 mg/mouse 62.11 65.29
G IGL 0.75  0.75
mg/mouse
47.17 48.42
H GC 15 mg/mouse 65.58 68.01
I LC 15 mg/mouse 66.54 64.14
J IGL 7.5  .7.5
mg/mouse
83.62 68.73
K GC 75 mg/mouse 41.78 45.74
L LC 75 mg/mouse 64.00 65.28
M IGL 37.5  37.5
mg/mouse
55.22 55.35
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The Effect of -Glycosphingolipids Is
Dependent on the CD1d Receptor
Proliferation of NKT hybridoma cells (DN32.D3) in the
presence of spleen-derived dendritic cells was assessed
by 3Hthymidine incorporation assay. The administration
of -IGL stimulated NKT cell proliferation, in contrast with
-GC or -LC administration alone, which resulted in NKT
cell inhibition (122%, 77%, and 76%, respectively, vs.
phosphate buffered saline PBS-treated cells, P 0.005;
Figure 2). The role of CD1d in this effect was determined
by blocking the CD1d receptor with an anti-CD1d antibody,
resulting in stimulation of cell proliferation for -GC and
-LC-treated groups (P  0.005; Figure 2). GalCer in-
duced a 50% increase in NKT proliferation, which was
blocked by the anti-CD1d antibody.
Downstream Effects of -Glycosphingolipids on
STAT 1, 3, and 6 Pathways, and Liver Injury
Alterations of raft microdomains by -ligands was asso-
ciated with decreased STAT1 levels in these fractions
(Figure 3A). STAT3 levels within raft fractions were in-
creased in -LC- and -IGL-treated cells, in contrast to a
decrease in -GC-treated cells.
In the ConA NKT-dependent immune hepatitis model,
splenic STAT1 phosphorylation decreased by 11% fol-
lowing GalCer treatment compared with a 51% de-
crease in -GC-treated mice (Figure 3B, P  NS). Ad-
ministration of -GC to GalCer-treated mice, however,
significantly increased STAT1 phosphorylation (30%,
Figure 1. A: Effect of -structured ligands on the lipid raft protein flotillin-2. Administration of -structured glycosphingolipids to DN32.D3NKT hybridoma cells
in the presence of dendritic cells led to prominent flotillin-2 recruitment to raft fractions. The upper panel is a representative Western blot indicating the expression
of flotillin-2. The lower panel is a representative dot blot indicating the expression of GM1. The numbers in both panels indicate the fraction number of samples
obtained from a Nycodenz linear step gradient. B: Effect of treatment of Ob/Ob mice with -glycosphingolipids for 6 weeks on glucose intolerance (P  0.005
for B and D versus A), serum triglycerides (P  0.005 for D versus A), intrahepatic fat accumulation, and liver weight (P  0.005 for B, C, and D versus A).
Experimental groups are specified in Table 1. Bars shows SD. *P  0.05, **P  0.001.
Figure 2. Effect of -glycosphingolipids with or without anti-CD1d antibody on
NKT cell proliferation in vitro. A thymidine incorporation assay was conducted,
and the percentage of change from PBS-treated controls is shown.
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P  0.005; data not shown). Hepatic STAT6 expression
increased by 62% (Figure 3B, P  0.005), along with a
112% increase in serum IL-4 levels following treatment with
-GC (data not shown). In contrast, a small decrease in
STAT 6 expression was detected following GalCer treat-
ment. STAT6 phosphorylation was not detectable.
-GC treatment in ConA hepatitis was associated with a
decrease in intrahepatic NKT cell number, in contrast with a
significant increase in NKT cell number in GalCer-treated
mice (P  0.005; Figure 3C). Administration of -GC to
GalCer-treated mice significantly suppressed the intrahe-
patic NKT cell number (66% decrease versus control, P 
0.05). These effects of -GC were associated with protec-
tion of the liver from GalCer-induced, immune-mediated
damage. Administration of GalCer led to increased serum
transaminase levels versus the control, in contrast with de-
creased levels when -GC was co-administered with
GalCer (increases of 136% and 231% and decreases of
76% and 81% for AST and ALT, respectively, P  0.005;
Figure 3C). -GC treatment led to a marked decrease in
TUNEL-positive hepatocytes compared with the control
(82% decrease, P  0.05; Figure 3C). Administration of
-GC to GalCer-treated mice led to a 61% decrease in
apoptosis (P  0.05).
STAT1, STAT4, and STAT6 Phosphorylation Is
Dependent on the -Glycosphingolipid Dose
Different doses of -glycosphingolipids in the Con A hepa-
titis model affected STAT1and STAT4 phosphorylation and
STAT1, STAT4, and STAT6 expression in the spleen (Figure
4A). Alterations in doses and combinations of -glycosphin-
golipids were associated with qualitative alterations in NKT
Figure 3. A: Downstream effects of -ligands on STAT1 and STAT3 pathways.
Alterations in raft microdomains were associated with decreased STAT1 localization
in some of the cytosolic raft fractions of -ligand-treated cells and increased STAT3
localization in raft fractions of -LC- and -IGL-treated cells. B: In the mouse Con A
hepatitis model, splenic phosphorylated STAT1 decreased following treatment with
GalCer and -GC. Hepatic STAT6 expression increased following combined treat-
ment with GalCer and -GC. C: Serum transaminase activities, NKT cell numbers,
and TUNEL quantification of apoptotic cells for control and - and/or -glycolipid-
treated mice. *P  0.05.
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lymphocyte distribution (Figure 4B) and with disease ame-
lioration, as manifested by decreased AST and ALT levels
(Table 1). A correlation between the decrease in intrahepatic
NKT cells and liver enzymes was noted for mice treated with
-GC (groups B, E, and K) or IGL (groups D and J).
A decrease in STAT1 phosphorylation was noted for
most -glycosphingolipid-treated mice. The most signif-
icant decrease was noted for group G mice, which cor-
related with marked suppression of intrahepatic NKT lym-
phocytes and dramatically decreased serum ALT and
AST levels. STAT 4 phosphorylation was up-regulated by
-glycosphingolipid treatment.
-Glycosphingolipid Acyl Chain Length Determines
the NKT Cell-Mediated Anti-Tumor Effect
Administration of -GC12 and -LC8 suppressed hepa-
tocellular carcinoma growth. Maximal tumor volumes
were 0.63 (-GC12) and 0.19 (-LC8) compared with
1.22 (-GC8) and 2.72 mm3 (-LC12) (Figure 5A, P 
0.05). -GC12 and -LC8 exerted profound effects on
NKT and CD8 lymphocyte distribution, manifested by
increased intrahepatic NKT lymphocytes and decreased
intrahepatic CD8 T lymphocyte trapping (Figure 5B). The
liver/spleen NKT lymphocyte ratios were 2.6 (-GC12)
and 0.97 (-LC8) as compared with 0.35 (PBS) (P 
0.05). The spleen/liver CD4/CD8 lymphocyte ratios were
3.0 (-GC12) and 0.39 (-LC8) compared with 4.68
(PBS) (Figure 5B, P  0.005). These results suggest that
there is a correlation between lipid chain length and the
anti-tumor effect of NKT cells.
Discussion
The results of the present study indicated that -glyco-
sphingolipids affect STAT signaling pathways in CD1d
and flotillin-2 raft protein-dependent manners. The
-structure, the alteration of the carbon number in the
acyl chain, and the use of several combinations of -an-
alogues in different doses affected lipid raft structure,
followed by downstream effects on STAT proteins. These
-sphingolipid–induced effects on STAT signaling were
associated with beneficial effects in several models of
Figure 4. A: Effects of different ratios and doses of -ligands on phosphor-
ylated STAT1, STAT4, and STAT6 levels in the mouse Con A hepatitis model.
Treatments A–M are specified in Table 1. B: Effects of different ratios and
doses of -ligands on NKT lymphocyte distribution in the mouse Con A
hepatitis model. FACS analysis was preformed for CD3/NK1.1 surface mark-
ers on lymphocytes in the spleen and in the liver.
Figure 5. A: Influence of -glycolipid acyl chain length on the anti-tumor
effect. Hepatocellular carcinoma- bearing mice were treated with -ligands
for 6 weeks. Tumor volumes were reduced in -GC12- and -LC8-treated
mice compared with -GC8- and -LC12-treated mice. B: -GC12 and -LC8
increased intrahepatic NKT lymphocytes and decreased intrahepatic CD8 T
lymphocyte trapping.
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NKT cell-dependent, immune-mediated, metabolic, or
malignant disorders.
NKT lymphocytes respond to a variety of self ligands
and environmental stimuli, including disease-target anti-
gens, antigen-presenting cells, co-stimulatory signals,
soluble factors, and effector cells.37,38 The activation and
development of iNKT cells are guided by signals from
glycolipid metabolic pathways.39,40 iNKT cell function is
controlled by affinity thresholds for glycolipid antigens.24
The presentation of a neo-self glycolipid by an infec-
tious assault of antigen-presenting cells activates iNKT
cells, releasing pro-inflammatory or anti-inflammatory cy-
tokines.41 Several glycosphingolipids and phospholipids
derived from mammalian, bacterial, protozoan, and plant
species have been identified as possible natural ligands
for NKT cells.18–20,42 The semi-invariant TCRs can
recognize the mammalian glycosphingolipid isoglobotri-
hexosylceramide (iGb3) and microbial -glycuronylcer-
amides found in the cell walls of Gram-negative, lipopo-
lysaccharide-negative bacteria.43 iGb3 is candidate
molecule recognized by NKT cells under pathophysio-
logic conditions, such as cancer and autoimmune dis-
eases.43,44 A recent study indicated that iGb3 is unlikely
to be an endogenous CD1d lipid ligand determining thy-
mic iNKT selection.45 Although -GC was unable to ac-
tivate NKT hybridomas in a cell-free antigen-presentation
assay,24 it does have a role in loading natural V14J18
NKT antigens.
Lipid rafts are highly dynamic, submicroscopic assem-
blies enriched in glycosphingolipids and cholesterol with
saturated acyl chains.46 Specific signaling proteins seg-
regate into lipid rafts, and this process is important for
certain signal transduction events in a variety of cell
types.47 CD1d, a raft-localized receptor, is essential for
raft glycolipid-mediated activation and disruption of the
lipid raft structures blocks efficient signaling through
mCD1d.28 -glycosphingolipids are normal constituents
of cell membranes.48,49 The results of the present study
suggest that - glycolipid administration is associated
with prominent flotillin-2 recruitment to raft fractions in
vitro, but does not affect LCK or GM1.
Flotillin-2 is a plasma membrane-associated cytoplas-
mic protein that is enriched in detergent-insoluble mem-
brane fractions. Lipid raft flotillins are involved in tyrosine
kinase activation of protein kinases.50 On T cell stimula-
tion, flotillin-2 in T cells co-localizes with activated glyco-
sylphosphatidylinositol-linked proteins and the Fyn ki-
nase, participating in the assembly of protein complexes
essential for signal transduction.51 Increased association
of cellular flotillin with lipid raft microdomains during che-
mokine exposure is important in chemokine receptor sig-
naling and receptor partitioning in lipid rafts.52 Flotillin-2
is an integral component of raft microdomains, which
represent the units of function at the cell surface through
which ligand-stimulated STAT signaling is initiated.53
Methyl--cyclodextrin, which sequesters cholesterol and
disrupts plasma membrane rafts, inhibits IL-6- and inter-
feron--induced STAT signaling.
In the present study, downstream effects of -glyco-
sphingolipids on STAT protein pathways were demon-
strated in CD3NK1.1 cell-dependent models. Alter-
ations in STAT1 and STAT3 phosphorylation were noted
in cytosolic raft fractions in leptin-deficient ob/ob mice.
These downstream signaling changes were associated
with amelioration of several metabolic derangements. Di-
rect interactions of resident raft proteins, caveolins, and
flotillin with insulin-signaling molecules may organize
these molecules to ensure accurate transduction of the
insulin signal in adipocytes.47,54 -glycolipid-mediated
alterations of STAT1 and STAT6 pathways were also as-
sociated with amelioration of GalCer-induced liver dam-
age. Administration of -GC in the ConA hepatitis model
decreased STAT1 phosphorylation. The administration of
-GC to GalCer-treated mice also decreased STAT1
phosphorylation. Hepatic STAT6 expression increased
following combined -GC treatment, suggesting the up-
regulation of IL-4, an anti-inflammatory cytokine. Different
combinations of -ligands were tested, and the results
demonstrated versatile effects of -analogues on STAT1,
STAT4, and STAT6 expression and phosphorylation.
These changes in STAT pathways were associated with
altered NKT lymphocyte distribution and disease amelio-
ration. Administration of -GC had significant inhibitory
effects on intrahepatic NKT lymphocytes, and adminis-
tration of -GC to GalCer-treated mice suppressed the
intrahepatic NKT cell number.
Lipid rafts are required for efficient signal transduction
by CD1d and presentation of GalCer by CD1d to NKT
cells is facilitated by lipid rafts.55 Raft disruption inhibits
IL-6/STAT3 and interferon-/STAT1 signaling, suggesting
that almost all signaling by these cytokines is initiated in
raft microdomains.56 Blocking the CD1d receptor inhib-
ited NKT cell stimulation by the synthetic ligand GalCer,
but the effect of CD1d blocking on NKT activation via
natural - glycosphingolipids is not known. In the present
study, blocking the CD1d receptor stimulated -glycolip-
id-induced NKT cell proliferation. Our results suggest that
changes in the glycolipid structure may alter their binding
affinity. -glycosphingolipid recognition may depend on
CD1d and/or TCR interactions. If glycosphingolipids are
similarly bound by CD1d, it is most likely that recognition
will occur concomitantly with TCR binding. -glycosphin-
golipid binding by CD1d, however, presumably positions
the glycolipid where it can be recognized by the TCR.
Consequently, if the glycolipid is not “properly” pre-
sented by CD1d, it may not be effectively recognized by
the TCR. Interestingly, the combination of two -glyco-
sphingolipids (-IGL) overcame the CD1d-dependent in-
hibition of NKT activation induced by either of the -gly-
cosphingolipids alone.
Optimization of the NKT ligand structure has been
suggested as a potential tool to control immunomodula-
tory effects. The glycolipid sphingosine chain may be im-
portant for determining the affinity of the ligand for the CD1
groove in tumor antigen-presenting cells, thereby affecting
CD8 and NKT cell activation. The data presented here
suggest that the length of the -glycolipid sphingosine
chain is essential for determining the magnitude of CD8
redistribution, in breaking immune tolerance toward tumor
antigens, and in suppressing hepatocellular carcinoma
growth. Redistribution of lymphocyte subsets is a possible
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countermeasure to overcome immune-escape mecha-
nisms associated with tumor progression.
iNKT cells are unique in their tendency to simulta-
neously produce both Th1 and Th2 cytokines. Further-
more, iNKT cells enhance immunity in some disease
models, but are reported to suppress immunity in oth-
ers.24 The present results indicate that administration of
-glycosphingolipids exerts distinct effects on STAT1,
STAT4, and STAT6 protein expression on peripheral and
intrahepatic CD4, CD8, and NKT cell distribution, and
on Th1/Th2 cytokines. Thus, by affecting STAT signaling
pathways, -glycosphingolipids alter NKT lymphocyte
plasticity, possibly serving as “fine tuners” of the immune
system.30
Identifying antigens and determining lipid and carbo-
hydrate recognition requirements for NKT cells will allow
for the use of ligand analogues as fine tuners for NKT
immune regulation.57–59 The data presented here sug-
gest that the structure and dose of -glycosphingolipids
analogues may influence STAT signaling pathways in-
volved in cellular events. The identification of precise
structures or combinations of carbohydrates and lipids
recognized by CD3NK1.1 cells will facilitate the pro-
duction of biologically relevant epitopes via synthetic
chemistry. Approaches that interfere with glycolipid me-
tabolism or that introduce rationally designed glycosphin-
golipids are attractive means of immunomodulation that
may become valuable tools in NKT cell-based immune
therapies.
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